Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT ID: NCT05430399

Last Updated: 2023-07-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 349 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-21
• Study Completion Date: 2027-06-01

Brief Summary

It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Conditions

Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

utidelone

Group Type: EXPERIMENTAL

utidelone

Intervention Type: DRUG

Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Arm B

docetaxel

Group Type: ACTIVE_COMPARATOR

docetaxel

Intervention Type: DRUG

Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Interventions

utidelone

Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention Type: DRUG

docetaxel

Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed the informed consent form;
• Women aged ≥ 18 years;
• Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer;
• The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;
• Eastern Cooperative Oncology Group (ECOG) score [0-1] points;
• Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI;
• Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization;
• No previous chemotherapy for advanced breast cancer ;
• For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage;
• Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ;
• Patients with asymptomatic CNS metastases may be enrolled, if:

1. Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or

2. Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ;

• Adequate hematological, hepatic and renal function;
• Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment;
• Life expectancy of at least 12 weeks;
• Patients must be able to participate and comply with treatment and follow up.

Exclusion Criteria

• HER-2 positive (IHC 3+, or FISH positive);
• Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;
• Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy;
• Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study;
• Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs;
• Symptomatic central nervous system metastases;
• Pregnant or lactating women;
• Known or suspected hypersensitivity to any of the study drugs or excipients;
• Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ;
• Any other condition that the investigator considers inappropriate to participate in this trial .
• Use of corticosteroids is prohibited.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Hunan Cancer Hospital

OTHER

Sponsor Role: collaborator

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

wang shusen

Chief Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Shusen Wang

Guangzhou, Gangdong, China

Site Status: RECRUITING

Hunan Cancer Hospital

Hunan, Hunan, China

Site Status: NOT_YET_RECRUITING

Countries

China

Central Contacts

shusen wang, MD

Role: CONTACT

wangshs@sysucc.org.cn

+86-020-87342693

Facility Contacts

shusen wang, MD

Role: primary

wangshs@sysucc.org.cn

+86-020-87342693

Quchang OuYang, MD

Role: primary

oyqc1969@126.com

Other Identifiers

SYSU-2022-UCAN

Identifier Type: -

Identifier Source: org_study_id